Cited 2 times in
Selexipag as Add-on Therapy for Patients with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease: A Single-Center Retrospective Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김아영 | - |
dc.contributor.author | 정세용 | - |
dc.contributor.author | 정조원 | - |
dc.contributor.author | 최재영 | - |
dc.date.accessioned | 2021-04-29T17:10:14Z | - |
dc.date.available | 2021-04-29T17:10:14Z | - |
dc.date.issued | 2021-03 | - |
dc.identifier.issn | 1747-079X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/182215 | - |
dc.description.abstract | Purpose: This study examined the efficacy and safety of selexipag in treating pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD). Materials and Methods: We conducted a retrospective study of patients with CHD-associated PAH, treated with selexipag since December 2017. Thirteen adult patients (mean age, 45.4 years; women, 77%) were treated with selexipag as add-on therapy. Baseline characteristics, World Health Organization functional class, 6-minute walking distance (6MWD) test results, N-terminal pro-B-type natriuretic peptide levels, echocardiographic data, and incidence of side effects were assessed. Results: The majority of patients (12/13, 92.3%) experienced more than one treatment-associated complication; one patient dropped out of the study due to intolerable myalgia. The results of 6MWD test (from 299.2 ± 56.2 m to 363.8 ± 86.5 m, p = 0.039) and tricuspid regurgitation (TR) pressure gradient (from 84.7 ± 20.5 mmHg to 61.6 ± 24.0 mmHg, p = 0.018) improved and remained improved after selexipag treatment in 12 patients. Based on the results of a non-invasive risk assessment, 8 (66.7%) patients showed improvement, 3 (25.0%) showed no interval change, and the status of one patient (8.3%) deteriorated. Moreover, compared to patients treated with a low dosage, patients treated with a medium-to-high dosage showed a greater increase in 6MWD results (88.3 ± 26.4 m vs. 55.3 ± 27.6 m, p = 0.043) and a greater reduction in the TR pressure gradient (−33.7 ± 10.9 mmHg vs. −12.5 ± 12.0 mmHg, p = 0.015). Conclusion: Selexipag is an efficient pulmonary vasodilator as add-on therapy in treating CHD-associated PAH. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Blackwell Pub | - |
dc.relation.isPartOf | CONGENITAL HEART DISEASE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Selexipag as Add-on Therapy for Patients with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease: A Single-Center Retrospective Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | ;Dept. of Pediatrics (소아과학교실) | - |
dc.contributor.googleauthor | Se Yong Jung | - |
dc.contributor.googleauthor | Doyoung Jung | - |
dc.contributor.googleauthor | Ah Young Kim | - |
dc.contributor.googleauthor | Jae Hee Seol | - |
dc.contributor.googleauthor | Jung Min Park | - |
dc.contributor.googleauthor | Jo Won Jung | - |
dc.contributor.googleauthor | Jae Young Choi | - |
dc.identifier.doi | 10.32604/CHD.2021.014272 | - |
dc.contributor.localId | A04727 | - |
dc.contributor.localId | A03628 | - |
dc.contributor.localId | A03720 | - |
dc.contributor.localId | A04174 | - |
dc.relation.journalcode | J03406 | - |
dc.identifier.eissn | 1747-0803 | - |
dc.subject.keyword | Selexipag | - |
dc.subject.keyword | congenital heart disease | - |
dc.subject.keyword | pulmonary arterial hypertension | - |
dc.contributor.alternativeName | Kim, Ah Young | - |
dc.contributor.affiliatedAuthor | 김아영 | - |
dc.contributor.affiliatedAuthor | 정세용 | - |
dc.contributor.affiliatedAuthor | 정조원 | - |
dc.contributor.affiliatedAuthor | 최재영 | - |
dc.citation.volume | 16 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 233 | - |
dc.citation.endPage | 244 | - |
dc.identifier.bibliographicCitation | CONGENITAL HEART DISEASE, Vol.16(3) : 233-244, 2021-03 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.